Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-040845
Filing Date
2021-10-20
Accepted
2021-10-20 18:52:35
Documents
2
Period of Report
2021-10-13

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 7764
2 EX-24 DOCUMENT attachment1.htm EX-24 4060
  Complete submission text file 0000899243-21-040845.txt   13316
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Issuer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address
van Dijk Marcus Antonius (Reporting) CIK: 0001881659 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40908 | Film No.: 211335208